Trial Profile
OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Mercaptopurine; Methotrexate; Vincristine; Vindesine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 10 Feb 2016 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 21 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by European Clinical Trials Database.